Abstract:Purpose: Neurofibromatosis type 1(NF1) and type 2(NF2) are both autosomal dominantly inherited disorders and originate from schwann cells. This study was done to investigate the genetic and proteomic profiles of the tumours.Methods: Mutational analyses of neurofibromatosis type 1 and type 2 genes (NF1 and NF2) in 15 NF1 and NF2 patients were carried out using Sanger sequencing. TMT-labeled spectrometry analysis was used to identify the proteome of neurofibromatosis type 1 and type 2 relative to nerve controls. Loss of heterozygosity were analysed for the candidate gene EPB41L3. Protein expression of tumour tissues/cultures was assessed by Western blots and/or immunofluorescence.Finds: DNA sequencing showed frequent mutations within NF1 or NF2 in the neurofibromatosis type 1 and type 2, respectively. 159 proteins were significantly differentially expressed in NF1 compared with normal nerves, and 180 proteins were significantly differentially expressed in NF2 compared with normal nerves. Among these, 11 were found commonly up-regulated and 30 down-regulated in both tumors. Among the commonly significantly down-regulated proteins in both tumors we consistently find EPB41L3.The EPB41L3 tumour suppressor showed the most significantly decreased expression, and existed predominantly at the cytoplasm of HEI193 and NF1 cell cultures. Western blot analysis identified the down-regulation in the NF1 and NF2 association with neurofibromin and merlin, respectively. LOH of EPB41L3 was more common among neurofibromatosis type 1(seen in 3 of 5 tumors, 60%) and least common among neurofibromatosis type 2 (2 of 10, 20%).Interpretation: Our data first get an insight into the common molecular mechanisms of neurofibroma, that indicates the potential role of EPB41L3 as a therapeutic target for this tumor syndrome.Funding Information: This work was supported by the National Natural Science Foundation of China (Grant No. 82171366 to Wei Chen; No. 82070541, 81600625, both to ML; 81771332, 81571184, both to CZ; 82172820 to JZ).and Grant No. 19ZR1447400 to Wei Chen. Jiangxi province outstanding poject (Grant No.20202ACBL216005 to Wei Chen); the Health Industry Clinical Research Project of Shanghai Municipal Health Commission (No. 20204125, to ML; No. 201840110, to SX); the Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai (No. PWR12018-07, to CZ);the Key Discipline Construction Project of Pudong Health Bureau of Shanghai (No. PWZxk2017-23, to CZ); the Top-level Clinical Discipline Project of Shanghai Pudong (No. PWYgf2018-05, to CZ) .Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: Informed written consent was obtained from all patients donating tissue. This study was approved by the Institutional Review Board of the ethics committee of The shanghai east Hospital affiliated to School of Medicine, Shanghai Tong Ji University.

New insights into the molecular basis of spinal neurofibromatosis type 1

Genotype-Phenotype Correlations in Neurofibromatosis Type 1: A Single-Center Cohort Study

Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis

Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1

Genetic Analysis and Prenatal Diagnosis of a Sporadic Family with Neurofibromatosis Type 1

Proteomic and Genetic Analysis Reveals Loss of EPB41L3 Related to the Tumorigenesis of Neurofibromatosis Type 1 and Type 2

The Molecular Landscape of Glioma in Patients with Neurofibromatosis 1

Molecular dissection of somatic skeletal disease in Neurofibromatosis Type 1

Pictorial Review and Retrospective Study of Their Frequency in a Cohort of Patients

Spatial gene expression profiling unveils immuno-oncogenic programs of NF1-associated peripheral nerve sheath tumor progression

Pharmacological and Genomic Profiling of Neurofibromatosis Type 1 Plexiform Neurofibroma-Derived Schwann Cells

A Molecular Basis for Neurofibroma-Associated Skeletal Manifestations in NF1

Epco-22. Deep Phenotyping Identifies Truncating Mutations In The Nf2 Linker Domain Associated With Disease Severity In Neurofibromatosis Type Ii

Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas

The Investigation for Potential Modifier Genes in Patients with Neurofibromatosis Type 1 Based on Next-Generation Sequencing

Genotypes and clinical intervention of patients with neurofibromatosis type 1 associated dystrophic scoliosis

Clinical Presentation And Novel Pathogenic Variants Among 68 Chinese Neurofibromatosis 1 Children

CNS Glial Progenitors and Schwann Cells in Neurofibromatosis Type 1

Unraveling neuronal and metabolic alterations in neurofibromatosis type 1

Path-25. Consensus Recommendations For An Integrated Diagnostic Approach To Nerve Sheath Tumors Arising In The Setting Of Neurofibromatosis Type 1

Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches